PureTech Health plc (LON:PRTC - Get Free Report) shares rose 14.6% on Saturday . The stock traded as high as GBX 118 ($1.56) and last traded at GBX 118 ($1.56). Approximately 1,623,564 shares were traded during trading, an increase of 54% from the average daily volume of 1,056,594 shares. The stock had previously closed at GBX 103 ($1.36).
PureTech Health Stock Performance
The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. The firm has a market cap of £373.67 million, a PE ratio of -5.10 and a beta of 1.02. The firm's 50 day simple moving average is GBX 133.90 and its 200 day simple moving average is GBX 147.53.
PureTech Health Company Profile
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Further Reading
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
